Workflow
健帆生物(300529) - 2020 Q3 - 季度财报
300529JAFRON(300529)2020-10-20 16:00

Financial Performance - Net profit attributable to shareholders increased by 66.54% to CNY 186,780,990.40 for the reporting period[3] - Operating revenue for the reporting period reached CNY 445,657,614.95, representing a 42.64% increase year-on-year[3] - Basic earnings per share rose by 65.74% to CNY 0.2337 for the reporting period[3] - The company's total revenue for the year reached ¥1,315,332,870.12, representing a 35.42% increase compared to ¥971,272,392.55 in the same period last year[11] - The net profit for the period was ¥625,716,200.23, a 50.16% increase from ¥416,694,208.51 in the previous year[12] - The company reported a total profit of ¥220,657,263.47 for the current period, compared to ¥133,318,266.82 in the previous period, which is an increase of approximately 65.5%[28] - The company’s total comprehensive income for the current period was ¥186,442,515.37, compared to ¥111,627,385.18 in the previous period, indicating a growth of about 67.0%[30] - Net profit attributable to the parent company was ¥627,410,475.05, up 50.1% from ¥417,913,065.45 year-on-year[35] Assets and Liabilities - Total assets increased by 15.01% to CNY 2,869,093,935.58 compared to the end of the previous year[3] - The total assets of the company showed a significant increase, with inventories rising by 31.35% to ¥121,258,864.78, reflecting higher stock levels of finished goods and raw materials[10] - Non-current assets totaled CNY 1,112,646,688.26, compared to CNY 934,918,357.17 in the previous year, indicating an increase of about 19%[20] - Current liabilities decreased to CNY 233,967,719.50 from CNY 262,633,102.43, a reduction of approximately 11%[21] - The total liabilities amounted to 324,127,383.83 CNY, remaining stable compared to the previous year[49] - The company’s total current liabilities included accounts payable of CNY 25,640,615.34 and employee compensation payable of CNY 63,417,784.03[51] Cash Flow - The net cash flow from operating activities was CNY 154,752,965.10, up 21.97% compared to the same period last year[3] - Cash received from other operating activities amounted to ¥124,925,583.51, reflecting a 56.13% increase year-over-year[13] - The net cash flow from investment activities was -¥626,115,343.34, an improvement of 44.79% compared to the previous year[13] - The total cash and cash equivalents at the end of the period stood at CNY 868.38 million, significantly up from CNY 132.87 million at the end of the previous year[43] - The net cash flow from financing activities was negative CNY 266.80 million, worsening from negative CNY 195.44 million year-over-year[43] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,656[6] - The largest shareholder, Dong Fan, holds 43.90% of the shares, totaling 350,828,772 shares[6] Government Support - The company received government subsidies amounting to CNY 38,113,196.22 during the reporting period[4] - The company received tax refunds totaling ¥368,207.06, an increase of 121.44% compared to the previous year[13] Research and Development - Research and development expenses for the current period were ¥17,434,484.62, slightly down from ¥17,479,018.30 in the previous period, showing a decrease of about 0.3%[27] - Research and development expenses were ¥48,328,844.23, slightly up from ¥47,361,568.24, indicating continued investment in innovation[34] Compliance and Regulatory - The company has not reported any non-compliance issues or overdue commitments during the reporting period[16] - The company has received inquiries regarding its application for issuing convertible bonds, indicating ongoing regulatory engagement[15] Future Plans - The company plans to issue convertible bonds totaling up to ¥1 billion, approved by the board and shareholders[15] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[36]